[ 1 ] Marmor MD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors[J]. Int J Radiat Oncol Biol Phys, 2004, 58(3): 903-913.
[2]
[ 2 ] Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network[J]. Nat Rev Mol Cell Biol, 2001, 2(2): 127-137.
[3]
[ 3 ] Sato JD, Kawamoto T, Le AD, et al. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors[J]. Mol Biol Med, 1983, 1(5): 511-529.
[4]
[ 4 ] Camp ER, Summy J, Bauer TW, et al. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor[J]. Clin Cancer Res, 2005, 11(1): 397-405.
[5]
[ 5 ] Vecchione L, Jacobs B, Normanno N, et al. EGFR-targeted therapy[J]. Exp Cell Res, 2011, 317(19): 2765-2771.
[6]
[ 6 ] Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer[J]. J Clin Oncol, 2009, 27(5): 663-671.
[7]
[ 7 ] Van Cutsem E, K？hne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer[J]. N Engl J Med, 2009, 360(14): 1408-1417.
[8]
[ 8 ] Jy D, Siena S, Cassidy J, et al. Randomized, phaseⅢ trial of panitumumab with infusional fluorouracil,leucovorin,and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study[J]. J Clin Oncol, 2010, 28(31): 4697-4705.
[9]
[ 9 ] Wheeler DL, Huang S, Kruser TJ, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members[J]. Oncogene, 2008, 27(28): 3944-3956.
[10]
Rajput A, Koterba AP, Kreisberg JI, et al. A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo[J]. Cancer Res, 2007, 67(2): 665-673.
[11]
Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis[J]. Cancer Res, 2001, 61(13): 5090-5101.
[12]
Bianco R, Rosa R, Damiano V, et al. Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells[J]. Clin Cancer Res, 2008, 14(16): 5069-5080.
[13]
Ciardiello F, Bianco R, Caputo R, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy[J]. Clin Cancer Res, 2004, 10(2): 784-793.
[14]
Lu Y, Li X, Liang K, et al. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab[J]. Cancer Res, 2007, 67(17): 8240-8247.
[15]
Wheeler DL, Iida M, Kruser TJ, et al. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab[J]. Cancer Biol Ther, 2009, 8(8): 696-703.
[16]
Huang S, Benavente S, Armstrong EA, et al. p53 modulates acquired resistance to EGFR inhibitors and radiation[J]. Cancer Res, 2011, 71(22): 7071-7079.
[17]
Rosa R, Marciano R, Malapelle U, et al. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models[J]. Clin Cancer Res, 2013, 19(1): 138-147.
[18]
Yamada T, Takeuchi S, Kita K, et al. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer[J]. J Thorac Oncol, 2012, 7(2): 272-280.
[19]
Liska D, Chen CT, Bachleitner-Hofmann T, et al. HGF rescues colorectal cancer cells from EGFR inhibition via Met activation[J]. Clin cancer Res, 2011, 17(3): 472-482.
[20]
Sen M, Joyce S, Panahandeh M, et al. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer[J]. Clin cancer Res, 2012, 18(18): 4986-4996.
[21]
de Farias CB, Heinen TE, dos Santos RP, et al. BDNF/TrkB signaling protects HT-29 human colon cancer cells from EGFR inhibition[J]. Biochem Biophys Res Commun, 2012, 425(2): 328-332.
[22]
Pandey JP. Mechanism of resistance to cetuximab therapy in colorectal cancer: possible role of antibodies to immunoglobulin allotypes[J]. MABS, 2012, 4(5): 553-554.
[23]
Ogawa T, Liggett TE, Melnikov AA, et al. Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance[J]. Cell Cycle, 2012, 11(8): 1656-1663.
[24]
Johansson AC, Ansell A, Jerhammar F, et al. cancer-associated fibroblasts induce matrix metalloproteinase-mediated cetuximab resistance in head and neck squamous cell carcinoma cells[J]. Mol Cancer Res, 2012, 10(9): 1158-1168.
